{"id":243,"date":"2023-05-31T03:42:02","date_gmt":"2023-05-31T03:42:02","guid":{"rendered":"https:\/\/ppsg.ch\/?page_id=243"},"modified":"2026-10-22T04:44:13","modified_gmt":"2026-10-22T04:44:13","slug":"behandlung-mit-antidepressiva","status":"publish","type":"page","link":"https:\/\/ppsg.ch\/?page_id=243","title":{"rendered":"Behandlung mit Antidepressiva"},"content":{"rendered":"\r\n<h3 class=\"wp-block-heading\"><span style=\"color: #467aa7; font-family: 'Open Sans';\">Die moderne Behandlung der Depression<\/span><\/h3>\r\n<p><span style=\"font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<p class=\"wp-block-paragraph\"><span style=\"font-family: 'Open Sans';\">Im Jahr 2022 waren 8% der Bev\u00f6lkerung wegen psychischen Problemen in Behandlung.\u00a0 Die Depression ist die am h\u00e4ufigsten auftretende psychische Erkrankung. 10% der Schweizer Bev\u00f6lkerung weisen mittelschwere bis schwere Depressionssymptome auf. Frauen (12%) und junge Menschen (19%) sind h\u00e4ufiger betroffen als M\u00e4nner (8%) und Personen ab 65 Jahren (4%).<sup>1 <\/sup>Auf dem Genom (Gesamtheit aller Tr\u00e4ger der Erbinformation einer Zelle, wie Chromosomen, DNA, RNA) konnte die Wissenschaft bislang 44 Genorte identifizieren, die mit schweren Depressionen in Verbindung stehen.<sup>2\u00a0 <\/sup>Epigenetische Ver\u00e4nderungen (vererbbare Chromosomen-Modifikationen ohne Ver\u00e4nderungen der DNA-Sequenz) bestimmen, ob die Depression wirklich ausbrich.<sup>3 <\/sup>Umwelteinfl\u00fcsse bewirken unter anderem solche epigenetischen Ver\u00e4nderungen. Bei einer Depression kommt es zu Stoffwechselentgleisungen im Hirn. Dass der Stoffwechselhaushalt der Hirnzellen wieder ins Gleichgewicht kommt, ist das Ziel der medikament\u00f6sen Behandlung von Depressionen. Das menschliche Gehirn hat insgesamt 8.6\u00b710<sup>10<\/sup> <a href=\"https:\/\/ppsg.ch\/?page_id=2771\"><span style=\"color: #0000ff;\">Nervenzellen<\/span><\/a> (86&#8217;000\u2019000\u2019000). Jede Nervenzelle ist \u00fcber ungef\u00e4hr 10<sup>5<\/sup> <span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/ppsg.ch\/?page_id=2771\">Synapsen<\/a><\/span> (100&#8217;000) mit anderen Nervenzellen verbunden. Das <span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/ppsg.ch\/?page_id=2771\">neuronale Netzwerk<\/a> <\/span>des Menschen besitzt so zirka 8.6\u00b710<sup>15<\/sup> (8600\u2019000\u2019000\u2019000\u2019000) synaptische Verbindungen. Die Fortleitung des Impulses in der Hirnzelle ist ein elektrischer Vorgang. Der elektrische Impuls f\u00fchrt zur Aussch\u00fcttung eines \u00dcbertr\u00e4gerstoffs oder Hirnbotenstoffs (Neurotransmitter) in den Spalt zwischen den Hirnzellen (synaptischer Spalt). Es sind \u00fcber 100 erregende und hemmende Neurotransmitter bekannt.<\/span><\/p>\r\n<p><span style=\"font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<h6>\u00a0<\/h6>\r\n<figure class=\"wp-block-image\"><span style=\"font-family: 'Open Sans';\"><img decoding=\"async\" class=\"wp-image-3385\" src=\"http:\/\/www.psychiatrie-zh.ch\/wp-content\/uploads\/Abb_Hirn_Transmitter-300x169.png\" alt=\"\" \/><\/span><\/figure>\r\n<p class=\"wp-block-paragraph\"><span style=\"font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<h3 class=\"wp-block-heading\"><span style=\"color: #467aa7; font-family: 'Open Sans';\">Wirkungsweise von Antidepressiva<\/span><\/h3>\r\n<p><span style=\"font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<ul class=\"has-text-color wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Effekte auf Hirnbotenstoff-Ebene und Rezeptor-Ebene, Andockstelle einer Zelle, die meistens an der der Zelloberfl\u00e4che liegt.\u00a0 Wenn sich\u00a0 Hirnbotenstoffe an den Rezeptor binden, l\u00f6sen sie ein Signal in der Zelle aus (Schl\u00fcssel=Botenstoff und Schloss=Rezeptor). Nur wenn beide zusammen passen, kommt es zur Reaktion wie Transport, Metabolismus (Abbau), Agonismus (Aktivierung), Antagonismus (Blockierung), Modulation (Ver\u00e4nderungen)<\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Effekte auf Signal\u00fcbertragung\u00a0<\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Effekt auf Genexpression (wie ein Gen zum Ausdruck kommt und in Erscheinung tritt)<\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Effekte auf \u00fcbergeordneter Ebene des Zentralen Nerven Systems\u00a0 (Modulation der Plastizit\u00e4t des Hirns,\u00a0 Neubildung von Hirnzellen, Beschaffenheit der Rezeptoren)<\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Effekte auf Verhaltensebene (Stimmungsaufhellung, Aktivit\u00e4tssteigerung, Normalisierung der Denkst\u00f6rungen, Verminderung der St\u00f6rungen des vegetativen Nervensystems)<\/span><\/li>\r\n<\/ul>\r\n<p><span style=\"font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<h3 class=\"wp-block-heading\"><span style=\"color: #467aa7; font-family: 'Open Sans';\">Funktion der Neurotransmitter (Hirnbotenstoffe)<\/span><\/h3>\r\n<p><span style=\"font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<p class=\"wp-block-paragraph\"><span style=\"font-family: 'Open Sans';\">Serotonin (5-HT), Noradrenalin (NE), Dopamin (DA), \u03b3-Aminobutters\u00e4ure (GABA), Acetylcholin (Ach), Histamin, Glutamat und andere Hirnbotenstoffe sind an der Stoffwechselst\u00f6rung im Hirn beteiligt. Auch\u00a0 St\u00f6rungen des Hormonhaushaltes (Adrenalin, k\u00f6rpereigenes Kortisol) spielen \u00a0bei der Depression eine Rolle. GABA ist der wichtigste hemmende Botenstoff im Vorderhirn (Siehe Wirkung von <span style=\"color: #3366ff;\"><a style=\"color: #3366ff;\" href=\"https:\/\/ppsg.ch\/?page_id=237\">Benzodiazepinen<\/a>)<\/span><\/span><\/p>\r\n<p><span style=\"font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<h3 class=\"wp-block-heading\"><span style=\"color: #467aa7; font-family: 'Open Sans';\">\u25ba Serotonin, Noradrenalin und Dopamin<\/span><\/h3>\r\n<p><span style=\"color: #467aa7; font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<h4 class=\"wp-block-heading\"><span style=\"font-family: 'Open Sans';\">Funktionen der Hirnbotenstoffe<sup>4<\/sup><\/span><\/h4>\r\n<p><span style=\"color: #467aa7; font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<figure class=\"wp-block-image\"><span style=\"font-family: 'Open Sans';\"><a href=\"http:\/\/www.psychiatrie-zh.ch\/wp-content\/uploads\/Neurotransmitter_Funktion_22-1.bmp\"><img decoding=\"async\" class=\"wp-image-3202\" src=\"http:\/\/www.psychiatrie-zh.ch\/wp-content\/uploads\/Neurotransmitter_Funktion_22-1.bmp\" alt=\"\" \/><\/a><\/span><\/figure>\r\n<p><span style=\"font-family: 'Open Sans';\">\r\n\r\n\r\n\r\n\r\n\r\n<\/span><\/p>\r\n<h3 class=\"wp-block-heading\"><span style=\"color: #467aa7; font-family: 'Open Sans';\">\u25ba Glutamat<\/span><\/h3>\r\n<p><span style=\"font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<h4 class=\"wp-block-heading\"><span style=\"font-family: 'Open Sans';\">Wirkung von Glutamat<\/span><\/h4>\r\n<p><span style=\"font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<p class=\"wp-block-paragraph\"><span style=\"font-family: 'Open Sans';\">Glutamat ist der wichtigste erregende (exzitatorische) Neurotransmitter. Mehr als die H\u00e4lfte aller Synapsen im Gehirn verwenden Glutamat als Transmitter. N-Methyl-D-Aspartat Antagonisten bzw. \u00abGlutamat Rezeptor Blocker\u00bb wirken gegen die Exzitotoxizit\u00e4t (nervensch\u00e4digende \u00dcbererregung) durch den\u00a0Hirnbotenstoff Glutamat, wirken zudem antioxidativ, entz\u00fcndungshemmend und neuroprotektiv. Ketamin (Ketalar<sup>\u00ae<\/sup>), Esketamin (Spravato<sup>\u00ae<\/sup>), Memantin (Axura<sup>\u00ae<\/sup>, Ebixa<sup>\u00ae<\/sup>), Riluzol (Rilutek<sup>\u00ae<\/sup>), D-Cycloserin (Seromycin<sup>\u00ae<\/sup>), Minocyclin (Minocin<sup>\u00ae<\/sup>)\u00a0und andere Substanzen bzw. Medikamente\u00a0reduzieren\u00a0bzw.\u00a0verhindern die\u00a0Sch\u00e4digung der Hirnzellen durch Glutamat. Diese Medikamente sind Alternativen zu den Antidepressiva bei Therapieresistenz der Depression.<\/span><\/p>\r\n<p><span style=\"font-family: 'Open Sans';\">\r\n\r\n<\/span><\/p>\r\n<h3 class=\"wp-block-heading\">\u00a0<\/h3>\r\n<p><span style=\"font-family: 'Open Sans';\"><\/span><\/p>\r\n<h3><span style=\"color: #467aa7; font-family: 'Open Sans';\">Einteilung der Antidepressiva<\/span><\/h3>\r\n<p><span style=\"font-family: 'Open Sans';\"><\/span><\/p>\r\n<ul class=\"has-black-color has-text-color wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Trizyklische Antidepressiva (TCA)<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\"><u>Serotonin-Wiederaufnahmehemmer (S-RI)<\/u><\/span>\r\n<ul class=\"has-text-color wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Clomipramin (Anafranil<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\"><u>Noradrenalin-Wiederaufnahmehemmer (N-RI)<\/u><\/span>\r\n<ul class=\"has-text-color wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Maprotilin (Ludiomil\u00ae)<sup>5, 6<\/sup>, Nortriptylin (Nortrilen\u00ae)<sup>5, 6<\/sup><\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\"><u>Serotonin-\/Noradrenalin-Wiederaufnahmehemmer (SN-MM)<\/u><\/span>\r\n<ul class=\"has-text-color wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Amitriptylin (Saroten<sup>\u00ae<\/sup>), Doxepin (Sinquan<sup>\u00ae<\/sup>), Imipramin, (Tofranil\u00ae)<sup>5, 6<\/sup>, Trimipramin (Surmontil<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Selektiver Serotonin-Wiederaufnahmehemmer (S-RI)<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Citalopram (Seropram<sup>\u00ae<\/sup>), Escitalopram (Cipralex<sup>\u00ae<\/sup>), Fluoxetin (Fluctine<sup>\u00ae<\/sup>), Fluvoxamin (Floxyfral<sup>\u00ae<\/sup>), Paroxetin (Deroxat<sup>\u00ae<\/sup>), Sertralin (Zoloft<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Selektiver Noradrenalin-\/Serotonin-Wiederaufnahmehemmer (SN-RI)<\/span>\r\n<ul class=\"has-text-color wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Duloxetin (Cymbalta<sup>\u00ae<\/sup>), Venlafaxin (Efexor<sup>\u00ae<\/sup>), Milnacipran (Milnaneurax<sup>\u00ae<\/sup>)<sup>6, 7<\/sup><\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Noradrenalin Multimodal (NMM)<\/span>\r\n<ul class=\"has-text-color wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Mianserin (Tolvon<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Multimodales Antidepressivum (S-MM)<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Vortioxetin (Brintellix<sup>\u00ae<\/sup>)<sup>8<\/sup><\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Noradrenalin\/spezifisches Serotonin Antidepressivum (SN-RAn)<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Mirtazapin (Remeron<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Selektiver Noradrenalin-Wiederaufnahmehemmer (N-RI)<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Reboxetin (Edronax<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Serotonin-Antagonist\/- Wiederaufnahmehemmer (S-MM)<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Trazodon (Trittico<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Melatonin Multimodal (Mel-MM)<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Agomelatin (Valdoxan<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Glutamatmodulator<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Tianeptin (Tianeurax<sup>\u00ae<\/sup>, Stablon\u00ae)<sup>6, 7<\/sup><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Riluzol (Rilutek<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Dopamin-Wiederaufnahmehemmer (D-RIRe)<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Bupropion (Wellbutrin XR<sup>\u00ae<\/sup>, Zyban<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Reversibler selektiver Monoaminooxidase A-Hemmer (SNRevEI)<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Moclobemid (Aurorix<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Monoaminooxidasehemmer (SN-MM)<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Tranylcypromin (Jatrosom N<sup>\u00ae<\/sup>)<sup>6, 7<\/sup><\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Glutamat Rezeptor Antagonist (Glu-RAn)<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Memantin (Axura<sup>\u00ae<\/sup>, Ebixa<sup>\u00ae<\/sup>)<\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Donepezil (Aricept<sup>\u00ae<\/sup>)<\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Galantamin (Reminyl<sup>\u00ae<\/sup>)<\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Ketamine (Ketanest<sup>\u00ae<\/sup>)<\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Esketamin (Ketanest<sup>\u00ae<\/sup> S, Spravato<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Partieller Agonist des Glycin-Koagonisten des Glutamatrezeptors<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Cycloserin (Seromycin<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n\r\n\r\n\r\n<li><span style=\"font-family: 'Open Sans';\">Antioxidans, Glutamatmodulator, pro-inflammatorischer Zytokine Reduktor (IL-1, IL-6, IL-2, TNF-, IFN-\u03b3), anti-inflammatorische Zytokine IL-10 Regulator, Serotonin-, Dopamin-, Serotonin-\/Dopamintransporter Reduktor<\/span>\r\n<ul class=\"wp-block-list\">\r\n<li><span style=\"font-family: 'Open Sans';\">Minocyclin (Minocin<sup>\u00ae<\/sup>)<\/span><\/li>\r\n<\/ul>\r\n<span style=\"font-family: 'Open Sans';\"><\/span><\/li>\r\n<\/ul>\r\n<p><span style=\"font-family: 'Open Sans';\"><\/span><\/p>\r\n<p>&nbsp;<\/p>\r\n<h3><span style=\"color: #3366ff; font-family: 'Open Sans';\"><a style=\"color: #3366ff;\" href=\"https:\/\/cinp.org\/nomenclature\" target=\"_blank\" rel=\"noopener\"><span style=\"font-size: 16px;\"><span style=\"font-size: 18px;\"><strong>Neuroscience-based Nomenclature (NbN)<sup>9\u00a0<\/sup><\/strong><\/span><\/span><\/a><\/span><\/h3>\r\n<table style=\"height: 803px;\" width=\"717\">\r\n<tbody>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">dopamine reuptake inhibitor and releaser (D-RIRe)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Dopamin-\/Noradrenalin-Wiederaufnahmehemmer (NDRI)<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\">\u00a0<\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Allosterischer Serotonin-Wiederaufnahmehemmer (ASRI)<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">glutamate receptor antagonist (Glu-RAn)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Glutamat Rezeptor Antagonist<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">glutamate; yet to be determined (Glu)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Glutamatmodulator<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">melatonin multimodal (Mel-MM)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Melatonin-Agonist\/Serotonin Antagonist<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">N-methyl-D-aspartate (NMDA) receptor antagonist (Glu-RAn)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">N-Methyl-D-Aspartat Rezeptor Antagonist<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">norepinephrine multimodal (NMM)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Noradrenerges Antidepressivum mit Hemmung pr\u00e4synaptischer \u03b12-Rezeptor<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">norepinephrine reuptake inhibitor (N-RI)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Selektiver Noradrenalin-Wiederaufnahmehemmer (sNARI)<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">partial agonist of the glycine co-agonist of the glutamate receptor<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Partieller Agonist des Glycin-Koagonisten des Glutamatrezeptors<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">serotonin multimodal (S-MM)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Multimodales Antidepressivum, Serotonin-Antagonist\/- Wiederaufnahmehemmer (SARI)<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">serotonin, norepinephrine, dopamine multimodal enzyme inhibitor (SN-MM)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Monoaminooxidasehemmer (MAOI)<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">serotonin, norepinephrine, dopamine reversible enzyme inhibitor (SNRevEI)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Reversibler selektiver Monoaminooxidase A-Hemmer (MAO-A) (RIMA)<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">serotonin, norepinephrine multimodal (SN-MM)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Selektiver Noradrenalin-\/Serotonin-Wiederaufnahme-hemmer (SNRI)<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">serotonin, norepinephrine receptor antagonist (SN-RAn)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Noradrenalin\/spezifisches Serotonin Antidepressivum (NaSSA)<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">serotonin reuptake inhibitor (S-RI)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Selektiver Serotonin-Wiederaufnahmehemmer (SSRI)<\/span><\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">tricyclic antidepressant (TCA)<\/span><\/td>\r\n<td width=\"302\"><span style=\"font-family: 'Open Sans';\">Trizyklische Antidepressiva (TZA)<\/span><\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<h6>\u00a0<\/h6>\r\n<h6><span style=\"font-family: 'Open Sans';\"><span style=\"font-size: 9px;\"><span style=\"color: #6c6c6c; font-size: 10px;\"><sup>1<\/sup>Storni M, Lieberherr R, Kaeser M, Schneider S. (2023). Schweizerische Gesundheitsbefragung 2022, Neuch\u00e2tel, Schweizerische Eidgenossenschaft, Eidgen\u00f6ssisches Departement des Innern (EDI), Bundesamt f\u00fcr Statistik (BFS).<br \/><\/span><span style=\"font-size: 10px;\"><span style=\"color: #999999;\"><sup>2<\/sup><\/span><span style=\"color: #6c6c6c;\">Wray NR et al. Genome wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018 May;50(5):668-681.<br \/><\/span><span style=\"color: #6c6c6c;\"><span style=\"font-size: 10px;\"><sup>3<\/sup>Klengel T, Binder EB. (2015) FKBP5 allele-specific epigenetic modification in gene by environment interaction. Neuropsychopharmacology. 2015 Jan;40(1):244-246.<\/span><br \/><\/span><\/span><\/span><span style=\"color: #6c6c6c; font-size: 10px;\"><sup>4<\/sup>Modifiziert nach Healy D., McMonagle T. (1997). The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol, 11(4 Suppl)\/1997, S. 25-31.<br \/><\/span><span style=\"font-size: 10px; color: #6c6c6c;\"><sup>5<\/sup>In der Schweiz nicht mehr erh\u00e4ltlich.<br \/><sup>6<\/sup>In Deutschland erh\u00e4ltlich. <br \/><sup>7<\/sup>Keine Zulassung in der Schweiz durch Swissmedic.<br \/><sup>8<\/sup> Serotonin-Wiederaufnahmehemmer, Serotonin-1A-Rezeptoragonist, partieller Serotonin-1B-Rezeptorantagonist, Serotonin-1D-\/3-\/7-Rezeptorantagonist, Modulator des Serotonin, Noradrenalin , Dopamin , Histamin , Acetylcholin , GABA und Glutamat Systeme.<br \/><sup data-rich-text-format-boundary=\"true\">9<\/sup>Zohar J, Stahl S., Moller HJ, Blier P, Kupfer D, Correll C, Yamawaki S, Uchida H, Drago F, Goodwin G, Nutt D. 2019. NbN-2R \u2013 Neuroscience-based Nomenclature Second Edition &#8211; Revised. European College of Neuropsychopharmacology (ECNP).<\/span><\/span><\/h6>\r\n<p>&nbsp;<\/p>\r\n<p>&nbsp;<\/p>\r\n<h3><span style=\"color: #467aa7;\">Modern Treatment of Depression<\/span><\/h3>\r\n<p>In 2022, 8% of the population was receiving treatment for mental health issues. Depression is the most common mental illness. 10% of the Swiss population exhibits moderate to severe symptoms of depression. Women (12%) and young people (19%) are affected more frequently than men (8%) and people aged 65 and older (4%).<sup>1<\/sup> Scientists have so far identified 44 genetic loci on the genome (the totality of all carriers of a cell\u2019s genetic information, such as chromosomes, DNA, and RNA) that are associated with major depression. <sup>2<\/sup> Epigenetic changes (heritable chromosomal modifications without alterations to the DNA sequence) determine whether depression actually develops.<sup>3<\/sup> Environmental influences, among other factors, cause such epigenetic changes. Depression leads to metabolic imbalances in the brain. The goal of pharmacological treatment for depression is to restore the metabolic balance of brain cells. The human brain has a total of 8.6 \u00d7 10\u00b9\u2070 nerve cells (86,000,000,000). Each nerve cell is connected to other nerve cells via approximately 10\u2075 synapses (100,000). The human neural network thus has approximately 8.6 \u00d7 10\u00b9\u2075 (8,600,000,000,000,000) synaptic connections. The transmission of an impulse within a brain cell is an electrical process. The electrical impulse triggers the release of a neurotransmitter into the gap between the brain cells (synaptic cleft). Over 100 excitatory and inhibitory neurotransmitters are known.\u00a0<\/p>\r\n<p>&nbsp;<\/p>\r\n<p><a href=\"https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Recepors_Brain-cells_Synapses_2-1.png\"><img fetchpriority=\"high\" decoding=\"async\" class=\"alignnone  wp-image-3657\" src=\"https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Recepors_Brain-cells_Synapses_2-1.png\" alt=\"\" width=\"595\" height=\"335\" srcset=\"https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Recepors_Brain-cells_Synapses_2-1.png 2099w, https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Recepors_Brain-cells_Synapses_2-1-300x169.png 300w, https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Recepors_Brain-cells_Synapses_2-1-1024x576.png 1024w, https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Recepors_Brain-cells_Synapses_2-1-768x432.png 768w, https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Recepors_Brain-cells_Synapses_2-1-1536x864.png 1536w, https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Recepors_Brain-cells_Synapses_2-1-2048x1152.png 2048w\" sizes=\"(max-width: 595px) 100vw, 595px\" \/><\/a><\/p>\r\n<p>&nbsp;<\/p>\r\n<h3><span style=\"color: #467aa7;\">How Antidepressants Work<\/span><\/h3>\r\n<ul>\r\n<li>Effects at the level of neurotransmitters and receptors\u2014a binding site on a cell, usually located on the cell surface. When neurotransmitters bind to the receptor, they trigger a signal within the cell (key = neurotransmitter and lock = receptor). Only when both fit together does a reaction occur, such as transport, metabolism (breakdown), agonism (activation), antagonism (blocking), or modulation (changes)<\/li>\r\n<li>Effects on signal transduction<\/li>\r\n<li>Effects on gene expression (how a gene is expressed and manifests itself)<\/li>\r\n<li>Effects at the higher level of the central nervous system (modulation of brain plasticity, neurogenesis, receptor properties)<\/li>\r\n<li>Effects at the behavioral level (improved mood, increased activity, normalization of thought disorders, reduction of autonomic nervous system disorders)<\/li>\r\n<\/ul>\r\n<h3><span style=\"color: #467aa7;\">Function of neurotransmitter<\/span><\/h3>\r\n<p>Serotonin (5-HT), norepinephrine (NE), dopamine (DA), \u03b3-aminobutyric acid (GABA), acetylcholine (Ach), histamine, glutamate, and other neurotransmitters are involved in metabolic disturbances in the brain. Hormonal imbalances (adrenaline, endogenous cortisol) also play a role in depression. GABA is the most important inhibitory neurotransmitter in the forebrain (see Effects of Benzodiazepines).<\/p>\r\n<p>&nbsp;<\/p>\r\n<h3><span style=\"color: #467aa7;\">\u25ba Serotonin, Norepinephrine and Dopamine<\/span><\/h3>\r\n<h4>Function of neurotransmitter<sup>4 <\/sup><\/h4>\r\n<p><a href=\"https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Serotonin_Norepinephrine_Dopamie.bmp\"><img decoding=\"async\" class=\"alignnone  wp-image-3652\" src=\"https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Serotonin_Norepinephrine_Dopamie.bmp\" alt=\"\" width=\"543\" height=\"490\" srcset=\"https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Serotonin_Norepinephrine_Dopamie.bmp 1984w, https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Serotonin_Norepinephrine_Dopamie-300x271.jpg 300w, https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Serotonin_Norepinephrine_Dopamie-1024x925.jpg 1024w, https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Serotonin_Norepinephrine_Dopamie-768x694.jpg 768w, https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/10\/Serotonin_Norepinephrine_Dopamie-1536x1387.jpg 1536w\" sizes=\"(max-width: 543px) 100vw, 543px\" \/><\/a><\/p>\r\n<h3><span style=\"color: #467aa7;\">\u25ba Glutamate<\/span><\/h3>\r\n<h4>Effect of Glutamate<\/h4>\r\n<p>Glutamate is the most important excitatory neurotransmitter. More than half of all synapses in the brain use glutamate as a transmitter. N-methyl-D-aspartate (NMDA) antagonists, or \u201cglutamate receptor blockers,\u201d counteract excitotoxicity (nerve-damaging overexcitation) caused by the neurotransmitter glutamate; they also have antioxidant, anti-inflammatory, and neuroprotective effects. Ketamine (Ketalar\u00ae), esketamine (Spravato\u00ae), memantine (Axura\u00ae, Ebixa\u00ae), riluzole (Rilutek\u00ae), D-cycloserine (Seromycin\u00ae), minocycline (Minocin\u00ae), and other substances or medications reduce or prevent damage to brain cells caused by glutamate. These medications are alternatives to antidepressants in cases of treatment-resistant depression.<\/p>\r\n<h3><span style=\"color: #467aa7;\">Classification of Antidepressants<\/span><\/h3>\r\n<ul>\r\n<li>Tricyclic Antidepressants (TCAs)\r\n<ul>\r\n<li>Serotonin Reuptake Inhibitors (S-RI)\r\n<ul>\r\n<li>Clomipramine (Anafranil\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<li>Norepinephrine reuptake inhibitors (N-RI)\r\n<ul>\r\n<li>Maprotiline (Ludiomil\u00ae), Nortriptyline (Pamelor\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<li>Serotonin\/norepinephrine reuptake inhibitors (SN-MM)\r\n<ul>\r\n<li>Amitriptyline (Elavil\u00ae), doxepin (Sinequan\u00ae, Sinelor\u00ae), imipramine (Tofranil\u00ae), trimipramine (Surmontil\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Selective serotonin reuptake inhibitors (S-RI)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Citalopram (Celexa\u00ae), escitalopram (Lexapro\u00ae), fluoxetine (Prozac\u00ae), fluvoxamine (Luvox\u00ae), paroxetine (Paxil\u00ae), sertraline (Zoloft\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Selective norepinephrine\/serotonin reuptake inhibitors (SN-RI)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Duloxetine (Cymbalta\u00ae), venlafaxine (Effexor\u00ae), milnacipran (Toledomin\u00ae, Ixel\u00ae, Savella\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Multimodal norepinephrine (NMM)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Mianserin (Lerivon\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Multimodal antidepressant (S-MM)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Vortioxetine (Trintellix\u00ae)<sup>5<\/sup><\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Norepinephrine\/Specific Serotonin Antidepressant (SN-RAn)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Mirtazapine (Remeron\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Selective Norepinephrine Reuptake Inhibitor (N-RI)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Reboxetine (Edronax\u00ae, Norebox\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Serotonin antagonist\/reuptake inhibitor (S-MM)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Trazodone (Desyrel\u00ae, Oleptro\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Melatonin multimodal (Mel-MM)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Agomelatine (Valdoxan\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Glutamate modulator<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Tianeptine (Coaxil\u00ae, Stablon\u00ae, Tatinol\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Riluzole (Rilutek\u00ae, Exservan\u00ae, Tiglutik\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Dopamine reuptake inhibitor (D-RIRe)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Bupropion (Aplenzin\u00ae, Wellbutrin XR\u00ae, Zyban\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Reversible selective monoamine oxidase A inhibitor (SNRevEI)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Moclobemide (Aurorix\u00ae, Arima\u00ae, Manerix\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Monoamine oxidase inhibitor (SN-MM)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Tranylcypromine (Parnate\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Glutamate receptor antagonist (Glu-RAn)<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Memantine (Namenda\u00ae)<\/li>\r\n<li>Donepezil (Aricept\u00ae, Memac\u00ae)<\/li>\r\n<li>Galantamine (Razadyne\u00ae)<\/li>\r\n<li>Ketamine (Ketanest\u00ae, Ketalar\u00ae)<\/li>\r\n<li>Esketamine (Spravato\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Partial agonist of the glycine co-agonist of the glutamate receptor<\/li>\r\n<\/ul>\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<ul>\r\n<li>Cycloserine (Seromycin\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<ul>\r\n<li>Antioxidant, glutamate modulator, pro-inflammatory cytokine reducer (IL-1, IL-6, IL-2, TNF-, IFN-\u03b3), anti-inflammatory cytokine IL-10 regulator, serotonin, dopamine, and serotonin\/dopamine transporter reducer\r\n<ul>\r\n<li>Minocycline (Minocin\u00ae, Arestin\u00ae, Solodyn\u00ae, Minolira\u00ae)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<h3><span style=\"color: #467aa7;\">Neuroscience-based Nomenclature (NbN)<sup>6<\/sup><\/span><\/h3>\r\n<table>\r\n<tbody>\r\n<tr>\r\n<td width=\"313\">\r\n<p>\u00a0Dopamine reuptake inhibitor and releaser (D-RIRe)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Dopamine\/Norepinephrine Reuptake Inhibitor (NDRI)<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>&nbsp;<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Allosteric Serotonin Reuptake Inhibitor (ASRI)<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Glutamate receptor antagonist (Glu-RAn)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Glutamate Receptor Antagonist<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Glutamate; yet to be determined (Glu)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Glutamate Modulator<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Melatonin multimodal (Mel-MM)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Melatonin Agonist\/Serotonin Antagonist<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Norepinephrine multimodal (NMM)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Noradrenergic antidepressant with presynaptic \u03b12-receptor inhibition<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Norepinephrine reuptake inhibitor (N-RI)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Selective norepinephrine reuptake inhibitor (sNARI)<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Partial agonist of the glycine co-agonist of the glutamate receptor<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Partial agonist of the glycine coagonist of the glutamate receptor<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Serotonin multimodal (S-MM)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Multimodal antidepressant, serotonin antagonist\/reuptake inhibitor (SARI)<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Serotonin, norepinephrine, dopamine multimodal enzyme inhibitor (SN-MM)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Monoamine oxidase inhibitor (MAOI)<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Serotonin, norepinephrine, dopamine reversible enzyme inhibitor (SNRevEI)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Reversible selective monoamine oxidase A inhibitor (MAO-A) (RIMA)<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Serotonin, norepinephrine multimodal (SN-MM)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Selective norepinephrine\/serotonin reuptake inhibitor (SNRI)<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Serotonin, norepinephrine receptor antagonist (SN-RAn)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Norepinephrine\/specific serotonin antidepressant (NaSSA)<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Serotonin reuptake inhibitor (S-RI)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>Selective serotonin reuptake inhibitor (SSRI)<\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td width=\"313\">\r\n<p>Tricyclic antidepressant (TCA)<\/p>\r\n<\/td>\r\n<td width=\"313\">\r\n<p>&nbsp;<\/p>\r\n<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<p>&nbsp;<\/p>\r\n<p><span style=\"font-size: 8pt;\"><sup>1<\/sup>Storni M, Lieberherr R, Kaeser M, Schneider S. (2023). Schweizerische Gesundheitsbefragung 2022, Neuch\u00e2tel, Schweizerische Eidgenossenschaft, Eidgen\u00f6ssisches Departement des Innern (EDI), Bundesamt f\u00fcr Statistik (BFS).<\/span><br \/><span style=\"font-size: 8pt;\"><sup>2<\/sup>Wray NR et al. Genome wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018 May;50(5):668-681.<\/span><br \/><span style=\"font-size: 8pt;\"><sup>3<\/sup>Klengel T, Binder EB. (2015) FKBP5 allele-specific epigenetic modification in gene by environment interaction. Neuropsychopharmacology. 2015 Jan;40(1):244-246.<\/span><br \/><span style=\"font-size: 8pt;\"><sup>4<\/sup>Modifiziert nach Healy D., McMonagle T. (1997). The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol, 11(4 Suppl)\/1997, S. 25-31.<\/span><br \/><span style=\"font-size: 8pt;\"><sup>5<\/sup>Serotonin-Wiederaufnahmehemmer, Serotonin-1A-Rezeptoragonist, partieller Serotonin-1B-Rezeptorantagonist, Serotonin-1D-\/3-\/7-Rezeptorantagonist, Modulator des Serotonin, Noradrenalin , Dopamin , Histamin , Acetylcholin , GABA und Glutamat Systeme.<\/span><br \/><span style=\"font-size: 8pt;\"><sup>6<\/sup>Zohar J, Stahl S., Moller HJ, Blier P, Kupfer D, Correll C, Yamawaki S, Uchida H, Drago F, Goodwin G, Nutt D. 2019. NbN-2R \u2013 Neuroscience-based Nomenclature Second Edition \u2013 Revised. European College of Neuropsychopharmacology (ECNP).<\/span><\/p>\r\n<h6><span style=\"color: #999999;\"><\/span><\/h6>\r\n","protected":false},"excerpt":{"rendered":"<p>Die moderne Behandlung der Depression Im Jahr 2022 waren 8% der Bev\u00f6lkerung wegen psychischen Problemen in Behandlung.\u00a0 Die Depression ist die am h\u00e4ufigsten auftretende psychische Erkrankung. 10% der Schweizer Bev\u00f6lkerung weisen mittelschwere bis schwere Depressionssymptome auf. Frauen (12%) und junge Menschen (19%) sind h\u00e4ufiger betroffen als M\u00e4nner (8%) und Personen ab 65 Jahren (4%).1 Auf<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":19,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"class_list":["post-243","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v28.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Behandlung mit Antidepressiva -<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppsg.ch\/?page_id=243\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Behandlung mit Antidepressiva\" \/>\n<meta property=\"og:description\" content=\"Die moderne Behandlung der Depression Im Jahr 2022 waren 8% der Bev\u00f6lkerung wegen psychischen Problemen in Behandlung.\u00a0 Die Depression ist die am h\u00e4ufigsten auftretende psychische Erkrankung. 10% der Schweizer Bev\u00f6lkerung weisen mittelschwere bis schwere Depressionssymptome auf. Frauen (12%) und junge Menschen (19%) sind h\u00e4ufiger betroffen als M\u00e4nner (8%) und Personen ab 65 Jahren (4%).1 Auf\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppsg.ch\/?page_id=243\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/linkedin.com\/in\/bruno-kaegi-795761111\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-22T04:44:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppsg.ch\/wp-content\/uploads\/2023\/04\/Fotolia_139857590_M-Kopie-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1715\" \/>\n\t<meta property=\"og:image:height\" content=\"1108\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@home\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"12\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ppsg.ch\\\/?page_id=243\",\"url\":\"https:\\\/\\\/ppsg.ch\\\/?page_id=243\",\"name\":\"Behandlung mit Antidepressiva -\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ppsg.ch\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ppsg.ch\\\/?page_id=243#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ppsg.ch\\\/?page_id=243#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.psychiatrie-zh.ch\\\/wp-content\\\/uploads\\\/Abb_Hirn_Transmitter-300x169.png\",\"datePublished\":\"2023-05-31T03:42:02+00:00\",\"dateModified\":\"2026-10-22T04:44:13+00:00\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ppsg.ch\\\/?page_id=243\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/ppsg.ch\\\/?page_id=243#primaryimage\",\"url\":\"http:\\\/\\\/www.psychiatrie-zh.ch\\\/wp-content\\\/uploads\\\/Abb_Hirn_Transmitter-300x169.png\",\"contentUrl\":\"http:\\\/\\\/www.psychiatrie-zh.ch\\\/wp-content\\\/uploads\\\/Abb_Hirn_Transmitter-300x169.png\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ppsg.ch\\\/#website\",\"url\":\"https:\\\/\\\/ppsg.ch\\\/\",\"name\":\"ppsg\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ppsg.ch\\\/#organization\"},\"alternateName\":\"Psychiatrische Praxis St. Gallen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ppsg.ch\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ppsg.ch\\\/#organization\",\"name\":\"Psychiatrische Praxis St. Gallen | PPSG\",\"alternateName\":\"Psychiatrische Praxis St. Gallen\",\"url\":\"https:\\\/\\\/ppsg.ch\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/ppsg.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ppsg.ch\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Bild_Website-Link-fuer-E-Mail.jpg\",\"contentUrl\":\"https:\\\/\\\/ppsg.ch\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Bild_Website-Link-fuer-E-Mail.jpg\",\"width\":1114,\"height\":720,\"caption\":\"Psychiatrische Praxis St. Gallen | PPSG\"},\"image\":{\"@id\":\"https:\\\/\\\/ppsg.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/linkedin.com\\\/in\\\/bruno-kaegi-795761111\",\"https:\\\/\\\/x.com\\\/home\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Behandlung mit Antidepressiva -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppsg.ch\/?page_id=243","og_locale":"de_DE","og_type":"article","og_title":"Behandlung mit Antidepressiva","og_description":"Die moderne Behandlung der Depression Im Jahr 2022 waren 8% der Bev\u00f6lkerung wegen psychischen Problemen in Behandlung.\u00a0 Die Depression ist die am h\u00e4ufigsten auftretende psychische Erkrankung. 10% der Schweizer Bev\u00f6lkerung weisen mittelschwere bis schwere Depressionssymptome auf. Frauen (12%) und junge Menschen (19%) sind h\u00e4ufiger betroffen als M\u00e4nner (8%) und Personen ab 65 Jahren (4%).1 Auf","og_url":"https:\/\/ppsg.ch\/?page_id=243","article_publisher":"https:\/\/linkedin.com\/in\/bruno-kaegi-795761111","article_modified_time":"2026-10-22T04:44:13+00:00","og_image":[{"width":1715,"height":1108,"url":"https:\/\/ppsg.ch\/wp-content\/uploads\/2023\/04\/Fotolia_139857590_M-Kopie-2.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@home","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"12\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ppsg.ch\/?page_id=243","url":"https:\/\/ppsg.ch\/?page_id=243","name":"Behandlung mit Antidepressiva -","isPartOf":{"@id":"https:\/\/ppsg.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppsg.ch\/?page_id=243#primaryimage"},"image":{"@id":"https:\/\/ppsg.ch\/?page_id=243#primaryimage"},"thumbnailUrl":"http:\/\/www.psychiatrie-zh.ch\/wp-content\/uploads\/Abb_Hirn_Transmitter-300x169.png","datePublished":"2023-05-31T03:42:02+00:00","dateModified":"2026-10-22T04:44:13+00:00","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppsg.ch\/?page_id=243"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/ppsg.ch\/?page_id=243#primaryimage","url":"http:\/\/www.psychiatrie-zh.ch\/wp-content\/uploads\/Abb_Hirn_Transmitter-300x169.png","contentUrl":"http:\/\/www.psychiatrie-zh.ch\/wp-content\/uploads\/Abb_Hirn_Transmitter-300x169.png"},{"@type":"WebSite","@id":"https:\/\/ppsg.ch\/#website","url":"https:\/\/ppsg.ch\/","name":"ppsg","description":"","publisher":{"@id":"https:\/\/ppsg.ch\/#organization"},"alternateName":"Psychiatrische Praxis St. Gallen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppsg.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/ppsg.ch\/#organization","name":"Psychiatrische Praxis St. Gallen | PPSG","alternateName":"Psychiatrische Praxis St. Gallen","url":"https:\/\/ppsg.ch\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/ppsg.ch\/#\/schema\/logo\/image\/","url":"https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/05\/Bild_Website-Link-fuer-E-Mail.jpg","contentUrl":"https:\/\/ppsg.ch\/wp-content\/uploads\/2026\/05\/Bild_Website-Link-fuer-E-Mail.jpg","width":1114,"height":720,"caption":"Psychiatrische Praxis St. Gallen | PPSG"},"image":{"@id":"https:\/\/ppsg.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/linkedin.com\/in\/bruno-kaegi-795761111","https:\/\/x.com\/home"]}]}},"_links":{"self":[{"href":"https:\/\/ppsg.ch\/index.php?rest_route=\/wp\/v2\/pages\/243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ppsg.ch\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ppsg.ch\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ppsg.ch\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ppsg.ch\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=243"}],"version-history":[{"count":37,"href":"https:\/\/ppsg.ch\/index.php?rest_route=\/wp\/v2\/pages\/243\/revisions"}],"predecessor-version":[{"id":3727,"href":"https:\/\/ppsg.ch\/index.php?rest_route=\/wp\/v2\/pages\/243\/revisions\/3727"}],"wp:attachment":[{"href":"https:\/\/ppsg.ch\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}